Bias Assessment in Progression-Free Survival Analysis Using Interval-Censored Methods - Interval-Censored-Time-to-Event Data: Methods and Applications - page 306

dataBreastCancer;
setRT(in=ina)RCT;
ifinathenTherapy=1;
elseTherapy=2;
ifrTime=.thenevent=0;
elseevent=1;
formatTherapyRx.;
run;
***************************************************
*GeneralizedLogrankTest
***************************************************
%ICSTEST(data=BreastCancer,left=lTime,right=rTime,group=Therapy);
***************************************************
*Finkelstein ' smethod
***************************************************
%Intev_Cens(Dsin=BreastCancer,LeftT=lTime,RightT=rTime,Cnsr=event,
RgtCnV=61,TrtGrp=Therapy,Covar=,Mclass=,OptFunc=1,
TrtEst=EstB,TrtTest=Test,OutDrv=,SmPtb=,SmLen=1,Rdn=1);
Bibliography
Bedikian, A. Y., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U.,
Pavlick, A. C., DeConti, R., Hersh, E. M., Hersey, P., et al. (2006). Bcl-2 antisense
(oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The
oblimersen melanoma study group. Journal of Clinical Oncology 24, 4738{4745.
Bhattacharya, S., Fyfe, G., Gray, R. J., and Sargent, D. J. (2009). Role of sensitivity
analyses in assessing progression-free survival in late-stage oncology trials. Journal
of Clinical Oncology 27, 5958{5964.
Dancey, J. E., Dodd, L. E., Ford, R., Kaplan, R., Mooney, M., Rubinstein, L.,